Physician profile
Thomas Ence
NPI 1497779508
$10,618.06
in general payments reported to CMS, 2019-2025
37 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,687 · 2020: $834 · 2021: $1,114 · 2022: $1,886 · 2023: $2,147 · 2024: $1,582 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,097.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,165.08 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,732.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,441.17 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $529.11 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $451.85 | 2021-2024 | Tezspire |
| Insmed, INC. | $412.47 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $362.88 | 2019-2024 | Dupixent |
| Philips North America LLC | $297.99 | 2019-2024 | (8874) Incourage |
| Janssen Pharmaceuticals, INC | $284.15 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $254.85 | 2019-2023 | |
| Mylan Specialty L.P. | $253.09 | 2019-2024 | Yupelri |
| Pulmonx Corporation | $229.01 | 2022-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Gilead Sciences, INC. | $226.42 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $200.05 | 2019-2025 | Uptravi, Opsynvi |
| Genzyme Corporation | $176.83 | 2019-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.